Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

87 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes in MV4-11 cells upon SMARCA4 knock-down and PFI-3 treatment

ABSTRACT: Pharmacological inhibition of the SMARCA4 bromodomain inhibited human leukemic cell proliferation, phenocopying SMARCA4 knockdown in these cells. We performed microarray analysis of global gene expression changes in MV4-11 cells after 6 days of PFI-3 treatment and after SMARCA4 knock-down. With this analysis we identified several genes whose expression was similarly up- or down-regulated upon inhibitor treatment and SMARCA4 depletion. Human acute monocytic leukemia cells (MV4-11, ACC 102) were lentivirally transduced with shRNA taregting SMARCA4 (KD) or with a negative control shRNA (Scr). In a parallel experiment MV4-11 cells were treated for 6 days with 10 uM PFI-3, which is SMARCA4, SMARCA2 and PBRM1 bromodomain inhibitor, or DMSO as a negative control. All sample types were prepared in triplicates.

ORGANISM(S): Homo sapiens

SUBMITTER: Kristian Helin

PROVIDER: E-GEOD-67920 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Gene expression changes in MV4-11 cells upon SMARCA4 knock-down and PFI-3 treatment

Project description:Pharmacological inhibition of the SMARCA4 bromodomain inhibited human leukemic cell proliferation, phenocopying SMARCA4 knockdown in these cells. We performed microarray analysis of global gene expression changes in MV4-11 cells after 6 days of PFI-3 treatment and after SMARCA4 knock-down. With this analysis we identified several genes whose expression was similarly up- or down-regulated upon inhibitor treatment and SMARCA4 depletion.

2015-07-12 | GSE67920 | GEO

Targeting of SMARCA4 bromodomain selectively inhibits leukemic cell proliferation

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-07-12 | E-GEOD-67924 | biostudies-arrayexpress

Comparation the mRNA Expression Profile of the MV4-11 Sorafenib Resistant Cells and the Parental Cells

Project description:Our gene set analysis of MV4-11-R versus MV4-11 indicated decreased depolarization of mitochondria and mitochondrial membrane, mitochondrial dysfunction and anti-apoptosis as other top ranked molecular or cellular functions of differential gene sets. expression of most genes encoding glycolytic enzymes was up-regulated in MV4-11-R cells we revealed a metabolic alteration in sorafenib-resistant cell lines with mitochondrial respiration deficiency, leading to substantial decrease of mitochondria-derived ATP generation and a significant increase in glycolytic activity to maintain sufficient ATP production. Our study revealed a metabolic signature of sorafenib resistance and indicated that increase of glycolytic activity including upregulation of major glycolytic enzymes may be viewed as a marker for early detection of sorafenib resistance in AML patients with FLT3/ITD mutation and glycolytic inhibitors warrant further investigation as alternative therapeutic agents for sorafenib-resistant cells Sorafenib resistant cells MV411-R VS. parental MV4-11 cells. Biological replicates: 3 control replicates, 3 treated replicates.

2016-08-01 | E-GEOD-74666 | biostudies-arrayexpress

Next generation sequencing identifies small RNA expression in FLT3-ITD+ AML (MV4-11) cell lines

Project description:The expression level of microRNAs in FLT3-ITD+ AML is unknown. Using empty vector (EV) lentiviral CRISPR-Cas9 infected FLT3-ITD+ AML cell lines (MV4-11 cells), we performed next generation RNA sequencing on small RNAs to determine microRNA expression level in these cells. We found a variety of evolutionarily conserved and non-conserved microRNAs expressed in our cells of interest. Small RNAseq on EV lentiviral CRISPR-Cas9 infected MV4-11 cell lines was performed on triplicate cultures.

2016-07-01 | E-GEOD-71543 | biostudies-arrayexpress

Expression profile of wild type (WT) vs miR-155-/- in FLT3-ITD+ AML (MV4-11) cell lines

Project description:The expression profile in miR-155-/- FLT3-ITD+ AML is unknown. Using empty vector (EV) or two distinct miR-155 (S3 or S10) lentiviral CRISPR-Cas9 infected FLT3-ITD+ AML cell lines (MV4-11 cells), we performed next generation RNA sequencing to determine the expression profile in these cells dependent on miR-155. We found a number of pathways dysregulated, including STAT5 activation. RNAseq was performed on EV or miR-155 lentiviral CRISPR-Cas9 infected MV4-11 cell lines in triplicate cultures.

2016-07-01 | E-GEOD-71541 | biostudies-arrayexpress

Homo sapiens

Project description:Gene expression changes in MV4-11 cells upon SMARCA4 knock-down and PFI-3 treatment

| PRJNA281225 | ENA

E-GEOD-67920

Project description:Gene expression changes in MV4-11 cells upon SMARCA4 knock-down and PFI-3 treatment

2015-09-18 | E-GEOD-67920 | ExpressionAtlas

Aurora-A interactome in MV4-11 cells

Project description:To determine interactors of Aurora-A, HA tagged Aurora-A was immunoprecipitated from MV4-11 cells stably expressing HA tagged Aurora-A wild type and compared to MV4-11 cells expressing empty vector.

2020-09-28 | PXD019684 | Pride

Trophoblast stem cells (TSC) global transcriptome in stemness and differentiation conditions after treatment with PF1-3

Project description:Here we report a potent, acetyl-lysine competitive and cell active inhibitor, PFI-3, that tightly binds to the bromodomain present in BRG1/BRM and the fifth bromodomain in Polybromo (BAF180). The high specificity of PFI-3 was achieved based on a novel binding mode of a salicylic acid head group that led to the replacement of water molecules typically maintained in bromodomain inhibitor complexes. Embryonic stem cells exposure to PFI-3 led to deprivation of stemness and deregulated lineage specification. Furthermore, differentiation of trophoblast stem cells in the presence of PFI-3 was dramatically enhanced. TSC were treated with PF1-3 or control compound in stemness or differentiation conditions, 2 replicates were used for treatment in stemness and differentiation conditions together with 2 control replicates in stemness and one during differentiation; DFKZ genomics and proteomics

2015-12-16 | E-GEOD-65358 | biostudies-arrayexpress

Trophoblast stem cells (TSC) global transcriptome in stemness and differentiation conditions after treatment with PF1-3

2015-12-16 | GSE65358 | GEO